Page 65 - MemoriaBBN-Eng

www.ciber-bbn.es

• Multimodal imaging agents (SPECT, OI, CT and MRI). Nanoparticles for imaging diag-

nostic applications.

• Surface engineering for controlling cell proliferation on diverse materials.
• Development of solid phase methodology to synthesize biomolecules and other com-

pounds.

• Bionanotechnologies as new strategy to save compounds that failed on clinical or pre-
clinical phases.

• X J-B, P B, l K. o, l m. C, F A, m-
Most relevant AvierustArinGoAolorunoArstteseniBrAdAAñedoernAndolBeriCioerCe
des AlvArez. Total Synthesis and Stereochemical Assignment of BaringolinAngew. Chem. Int
scientific Ed. . 2013;52(30):7818 –7821.

articles
• Judit tullA-PuChe, miriAm GonGorA-Benítez, nuriA BAyo-PuXAn, Andrés m. FrAnCesCh, CArmen Cue-

vAs, FernAndo AlBeriCio. Enzyme-Labile Protecting Groups for the Synthesis of Natural Pro-
ducts: Solid-Phase Synthesis of Thiocoraline**Angewandte Chemie International Edition .
2013;52(22):5726 –5730.
ó

• P-G m; G-r y; J m m; s J; m-G J
elAyimenoArtAArCíAAmosesiCAesúsArtínAríAPenGlerAnolinAuiJArroosé
mAnuel; munt simon; FrAnCesCh Andrés m; CuevAs CArmen; tullA-PuChe Judit; AlBeriCio FernAndo. á
The first total synthesis of the cyclodepsipeptide pipecolidepsin ANature Communications.
2013;4(2352):2352.

• s-G l, P d, s Ch, G C, A F, r m. Biocompatible, multi-
imnrACiAulidoevrinrAndFilslBeriCiooyo
functional, and well-defined OEG-based dendritic platforms for biomedical applicationsOr- ó
ganic & Biomolecular Chemstry. 2013;11(24):4109-4121.

• AnA i. Fernndez-llAmAzAres, Jesús GArCíA, vAnessA soto-CerrAto, riCArdo Pérez-tomás, JAn sPenGler,
F A. N-Triethylene glycol (N-TEG) as a surrogate for the N-methyl group:
ernAndolBeriCio
application to Sansalvamide A peptide analogsChemComm. 2013;49(57):6430-6432.
ó

• In 2013, the Peptide and Nanoparticles Chemical Group has published a total of 41 publi-
Highlights
cations in international journals, some of them are high impact factor publications (Natu-
re Communications, Angewandte Chemie, Chemical Reviews, ACS Nano, Nanomedicine,

among others). Some of these publications described the synthesis of diverse marine-
derived drugs with potent antitumoral properties. These scientific advances were also

reportedindiversemedia(LaVanguardia,TV3,LaVozdeGalicia,Ara). Inadditionthe
Teaching Commission of the Higher Council of the University of Buenos Aires (UBA), in ò

Argentina, has granted the title of doctor “honoris causa” to Fernando Albericio, IP of the
group, in recognition of his research and teaching activities over the course of his broad

professional career.
• During this year, financial resources have been provided by various national and interna-

tional agencies, that include four national grants, one EC project, a regional valorization
project and a private foundation project. The group has four collaborative projects with

pharmaceutical and biotech companies founded by competitive grants (POLYSFERA, NA-
NOCARDIOCOCO, HUMANFARMAandMARINMAB,INNPACTO-MINECO).Thegroupalso

applied and granted other national collaborative project (INNPACTO-MINECO, MarinMab) 13
thatwasinitiatedin2013. Aprojectfromthegroupfocusedonthedevelopmentof per- 20
T
sonalizednanomedicineforbreastcancer, hasbeenawardedfinancialsupportfromthe OR
funds raised by the La Marat de TV3 2012 call, which was dedicated to cancer research. P
RE
The project will be developed in collaboration with other two CIBER BBN groups, the Na- L
nobiotechnology research group of the Institute of Biotechnology and Biomedicine of the A
NU
Autonomous University of Barcelona (UAB) and the CIBBIM - Nanomedicine from the Vall N
d’ Hebron Research Institute (VHIR).
A
N /
• Collaborations have been established and continued at the national (IBEC, IRB, CNIC, B
Hospital Vall d’Hebr, CIB-CSIC, Universitat Autnoma de Barcelona, Universitat de Barce- -B
R
lona, Universidad de Santiago de Compostela) and international levels (Chile, Argentina, BE
Brasill, Potugal, Netherlands, Belgium, South Africa and Denmark) as well as several co- CI

llaborative projects being carried out with companies form the pharmaceutical and biote- 65
chnology sectors.